跳至主要内容
临床试验/NCT01725698
NCT01725698Unknown1 期

The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect

Indonesia University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
入组人数
5
试验地点
1
主要终点
RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone union

研究概览

简要总结

This research is aimed to evaluate the combination of mesenchymal stem cell, HA-CaSO4, BMP-2, and implant in treating critical-sized bone defect.

In the presence of critical-sized bone defect whose defect size is more than 2.5 cm, bone will suffer a healing disturbance. In treating these conditions, the conventional method were vascularised bone grafting and bone transport. But the existing methods of treatment have many weaknesses Vascularized bone graft is a procedure with a high level of difficulty. Hence not every orthopaedic surgeon were able to perform it. It also takes more operating time and its failure rate is also quite high.

Meanwhile, external fixation which is applied with bone transport, was being often complained by the patient in terms of cosmetic and psychologically.

According to diamond concept of bone healing, there are four main factors that influence the bone healing. These factors are osteogenic factor (mesenchymal stem cell), osteconductive factor (HA-CaSO4), osteoinductive factor (bone morphogenetic protein-2) and mechanical component (implant). The potency of each component in fracture healing with/out bone defect has been proved in many studies. The combined effect of these components is often studied as well, but not in critical-sized bone defect.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
17 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subjects with critical size defect of bone

排除标准

  • subjects with patological fracture caused by primary or secondary bone malignancy, imunological deficit, active hepatitis or those who's under immunosuppresant therapy or other therapeutic modality that can interferes with bone healing.

研究组 & 干预措施

Stemcell

Experimental

Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant

干预措施: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant (Drug)

结局指标

主要结局

RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone union

时间窗: Before surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 years

plain radiograps will be taken to determine whether the bone has healed.

次要结局

  • Visual analog scale as the measure of clinical union(Before surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ismail Hadisoebroto Dilogo

PhD

Indonesia University

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Treatment of severe infections with mesenchymal stem cellsseptic shock
EUCTR2017-004123-67-FRCentre Hospitalier Régional Universitaire de Nancy66
已完成
1 期
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney DiseasePolycystic Kidney DiseaseChronic Renal Failure
NCT02166489Royan Institute6
进行中(未招募)
1 期
Bone marrow transplantation from a donor to a patient who have incompatible blood cells. Before transplantation, patients will receive a less intensive treatment with a low-dose chemiotherapy. The day of transplantation, patients will be injected with a population of blood cells from the donor as well as a specific cell population, named mesenchymal stem cells.Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission- ALL in Complete Remission- CML unresponsive/intolerant to Imatinib but not in blast crisis- Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis- MDS with < 5% blasts- Multiple myeloma not rapidly progressing- CLL- Non-Hodgkin’s lymphoma (aggressive NHL should have chemosensitive disease)- Hodgkin’s diseaseMedDRA version: 14.1Level: PTClassification code 10027703Term: Mismatched donor bone marrow transplantation therapySystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2009-014980-38-BECHU de Liège120
Unknown
1 期
Effect of Mesenchymal Stem Cell Transplantation for Lupus NephritisLupus Nephritis
NCT00659217Organ Transplant Institute, China20
终止
2 期
MSC and HSC Coinfusion in Mismatched MinitransplantsLeukemia, Myeloid, AcuteLeukemia, Lymphoblastic, AcuteLeukemia, Myelocytic, ChronicMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Lymphocytic, ChronicHodgkin's DiseaseLymphoma, Non-HodgkinMultiple Myeloma
NCT01045382University of Liege39